Role of ayurvedic treatment in knee osteoarthritis

Clinical Evaluation of a Specific Ayurvedic treatment regimen in the Management of Janugata Vata wsr to Knee Osteoarthritis An Open Clinical Trial - knee osteoarthritis

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/102530

Enrollment

200

Registered

2026-01-30

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M179- Osteoarthritis of knee, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged 40 60 years. Patient of either gender. Diagnosed cases of Janugata Vata (Knee Osteoarthritis). Willingness to participate and provide written informed consent.

Exclusion criteria

Exclusion criteria: Secondary OA due to trauma/known systemic illness. Rheumatoid arthritis, gout, septic arthritis. Severe systemic illness/unfit for trial interventions. Lactating or pregnant women.

Design outcomes

Primary

Measure	Time frame
1. To assess the role Specific Ayurvedic treatment regimen in the management of Janugata Vata (Knee Osteoarthritis). 2. To assess the improvement in functional ability and stiffness using the WOMAC index (Indian Modified CRD Pune Version). 3. To evaluate the effect of the regimen on pain reduction using the Visual Analog Scale (VAS) and WOMAC pain subscale. 4. To evaluate reduction in joint swelling and tenderness. Timepoint: 18 month	—

Measure

Time frame

1. To assess the role Specific Ayurvedic treatment regimen in the management of Janugata Vata (Knee Osteoarthritis). 2. To assess the improvement in functional ability and stiffness using the WOMAC index (Indian Modified CRD Pune Version). 3. To evaluate the effect of the regimen on pain reduction using the Visual Analog Scale (VAS) and WOMAC pain subscale. 4. To evaluate reduction in joint swelling and tenderness. Timepoint: 18 month

—

Secondary

Measure	Time frame
1. To assess the effect of the regimen on range of motion (ROM) of the knee joint. 2. To assess safety and tolerability by monitoring adverse effects. Timepoint: 18 month	—

Countries

India

Contacts

Public ContactDr Murali K

The Glocal university Saharanpur

muralivaidyaka@yahoo.com9447141281

Outcome results